|
1.
|
2025/08/01
|
|
Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy: The PRO-DUCE Randomized Clinical Trial
|
|
2.
|
2025/07
|
|
Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status.
|
|
3.
|
2025/06
|
|
Emotional Changes among Young Patients with Breast Cancer to Foster Relationship-Building with Their Partners: A Qualitative Study
|
|
4.
|
2025/05
|
|
A prospective cohort study of abemaciclib-induced interstitial lung disease in metastatic breast cancer after chemotherapy
|
|
5.
|
2025/04/26
|
|
Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors
|
|
6.
|
2025/04
|
|
Validation of the Symptom Illustration Scale within an electronic Patient‑Reported Outcomes Monitoring environment for metastatic breast cancer patients undergoing chemotherapy
|
|
7.
|
2025/03/25
|
|
Comparison of neoadjuvant and adjuvant chemotherapy for operable triple-negative breast cancer before the era of immune checkpoint inhibitors: A retrospective study from the Japanese National Clinical Database-Breast Cancer Registry
|
|
8.
|
2025/03/07
|
|
Is it appropriate to select patients for primary prophylactic use of pegfilgrastim based on the risk of febrile neutropenia?
|
|
9.
|
2025/03
|
|
Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression
|
|
10.
|
2025/01/24
|
|
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis
|
|
11.
|
2025/01
|
|
Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE)
|
|
12.
|
2024/12
|
|
Case of Radiation-Induced Angiosarcoma after Breast-Conserving Surgery with Hypofractionated Radiotherapy in a Japanese Patient.
|
|
13.
|
2024/11
|
|
Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14.
|
|
14.
|
2024/09
|
|
The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10.
|
|
15.
|
2024/07/16
|
|
Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial
|
|
16.
|
2024/07/09
|
|
The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10
|
|
17.
|
2024/07
|
|
Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment
|
|
18.
|
2024/06/18
|
|
Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14
|
|
19.
|
2024/05/26
|
|
A randomized trial of the impact of symptom monitoring using an electronic patient-reported outcome app on health-related quality of life in postmenopausal breast cancer patients receiving adjuvant endocrine therapy
|
|
20.
|
2024/05/15
|
|
Radiation-induced pleomorphic liposarcoma after hypofractionated radiotherapy following breast-conserving surgery: A case report and literature review.
|
|
21.
|
2024/05
|
|
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
|
|
22.
|
2024/03/29
|
|
Severe Pseudomonas aeruginosa Pneumonia in a Breast Cancer Patient Despite Pegfilgrastim Administration
|
|
23.
|
2024/03/19
|
|
Epithelial-mesenchymal transition in tumor cells is correlated with prognosis, and activated intra-tumor immunity is correlated with chemo-sensitivity in breast cancer patients with a non-pathological complete response to neoadjuvant chemotherapy.
|
|
24.
|
2024/03
|
|
Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy.
|
|
25.
|
2024/02
|
|
Lung Oligometastasis of Breast Cancer: Prospective Cohort Study of Treatment Strategies (SBP-06)
|
|
26.
|
2024/01
|
|
Long-Term Physical Activity and Body Composition After Exercise and Educational Programs for Breast Cancer: A Randomized Controlled Trial From the Setouchi Breast Project-10.
|
|
27.
|
2023/12/21
|
|
Preoperative suspicion of parathyroid carcinoma based on clinical findings
in a patient with primary hyperparathyroidism
|
|
28.
|
2023/12
|
|
Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study.
|
|
29.
|
2023/11/17
|
|
Long-Term Physical Activity and Body Composition After Exercise and Educational Programs for Breast Cancer: A Randomized Controlled Trial From the Setouchi Breast Project-10
|
|
30.
|
2023/11
|
|
An observational study of the impact of immediate breast reconstruction on perioperative inflammatory cytokines.
|
|
31.
|
2023/11
|
|
Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
|
|
32.
|
2023/09
|
|
Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
|
|
33.
|
2023/06
|
|
Impact of Immediate Breast Reconstruction on Survival of Breast Cancer Patients: A Single-Center Observational Study.
|
|
34.
|
2023/06
|
|
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
|
|
35.
|
2023/02
|
|
Gradient Boosted Tree Approaches for Mapping European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Onto 5-Level Version of EQ-5D Index for Patients With Cancer
|
|
36.
|
2023/02
|
|
Safety and Efficacy of a Well-Fitting Brassiere after Breast Reconstruction: A Qualitative Study
|
|
37.
|
2023/01
|
|
Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L
|
|
38.
|
2023/01
|
|
Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery.
|
|
39.
|
2022/12
|
|
Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study
|
|
40.
|
2022/12
|
|
Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients
|
|
41.
|
2022/11
|
|
Efficacy of Telemedicine Using Videoconferencing Systems in Outpatient Care for Patients With Cancer: A Systematic Review and Meta-Analysis
|
|
42.
|
2022/11
|
|
Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.
|
|
43.
|
2022/10
|
|
Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials.
|
|
44.
|
2022/09
|
|
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
|
|
45.
|
2022/08
|
|
Gene Expression Profiling between Patient Groups with High and Low Ki67 Levels after Short-term Preoperative Aromatase Inhibitor Treatment for Breast Cancer
|
|
46.
|
2022/08
|
|
Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer
|
|
47.
|
2022/08
|
|
Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial
|
|
48.
|
2022/06
|
|
Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial.
|
|
49.
|
2022/05
|
|
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
|
|
50.
|
2022/04
|
|
Older patients' experience of living with cognitive impairment related to hormone therapy for breast cancer: A qualitative study.
|
|
51.
|
2022/03
|
|
Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.
|
|
52.
|
2022/01
|
|
Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
|
|
53.
|
2022/01
|
|
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
|
|
54.
|
2022/01
|
|
Randomized Controlled Trial of Paper-Based at a Hospital versus Continual Electronic Patient-Reported Outcomes at Home for Metastatic Cancer Patients: Does Electronic Measurement at Home Detect Patients' Health Status in Greater Detail?
|
|
55.
|
2021/11/26
|
|
YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
|
|
56.
|
2021/10
|
|
A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study.
|
|
57.
|
2021/09
|
|
Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry.
|
|
58.
|
2021/08/01
|
|
Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
|
|
59.
|
2021/08
|
|
Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial.
|
|
60.
|
2021/06
|
|
Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer.
|
|
61.
|
2021/04/15
|
|
A Multicenter Study of Docetaxel at a Dose of 100 mg/m2 in Japanese Patients with Advanced or Recurrent Breast Cancer.
|
|
62.
|
2021/04
|
|
Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study.
|
|
63.
|
2016/02/12
|
|
The Japanese breast cancer society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition
|
|
Display 5 items
|
|
Display all(63)
|
